S. 27 was introduced in the 112th Congress, which has adjourned.

It has not yet been reintroduced.

You can increase the chances that the bill is revived in the new Congress by showing support for reintroduction.

Want to be notified when this bill is reintroduced?

View S. 27 (112th) report

What’s your position on S. 27 (112th)?

S. 27: Preserve Access to Affordable Generics Act

Summary: A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. (More Info)

S. 27 was introduced in the 112th Congress, which has adjourned. It has not yet been reintroduced.

What POPVOX Users Say

POPVOX Nation:
92% Support
8% Oppose
(581 users)

View Report & Comments

4 individuals support the reintroduction of S. 27 (112th). View report

532 users
49 users
order determined by social media popularity

Endorsing Organizations

Academy of Managed Care Pharmacy (AMCP) 1,540 Facebook fans 946 Twitter followers

AMCP is supportive of S. 27, the “Preserve Access to Affordable Generics Act,” which was passed by the Senate Judiciary Committee in July and is currently eligible for consideration by the full Senate. The legislation would presume illegal settlement agreements between brand-name and generic pharmaceutical manufacturers that would delay the entry of a generic drug to the marketplace. By delaying entry of generic drugs into the marketplace beyond original patent terms, these agreements keep drug prices artificially high.

The Federal Trade Commission (FTC) under both Democratic and Republican administrations has long considered these settlement agreements as anticompetitive. In his FY12 ...

Read full position statement.

* This organization’s position on this bill was entered by POPVOX.

National Retiree Legislative Network (NRLN)

Dear Senator Kohl:

On behalf of the more than 2 million retirees represented by the National Retiree Legislative Network (NRLN), I want to commend you for sponsoring S. 27, the Preserve Access to Affordable Generics Act. Your bill would do a great deal to enhance competition in America's pharmaceutical market by stopping anticompetitive agreements between brand name and generic drug manufactures. The NRLN believes as you do that increased competition among drug makers will help reverse the upward spiral in the cost of medicine for America’s consumers—especially retirees living on modest incomes.

The NRLN has long been ...

Read full position statement.

* This organization’s position on this bill was entered by POPVOX.